Lipocine Inc. Files 8-K for Other Events and Exhibits

Ticker: LPCN · Form: 8-K · Filed: Sep 30, 2024 · CIK: 1535955

Lipocine Inc. 8-K Filing Summary
FieldDetail
CompanyLipocine Inc. (LPCN)
Form Type8-K
Filed DateSep 30, 2024
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, SEC filing, financial-reporting

TL;DR

Lipocine filed a routine 8-K on 9/30/24 for other events and exhibits.

AI Summary

Lipocine Inc. filed an 8-K on September 30, 2024, reporting other events and financial statements. The filing does not detail specific transactions or material events, but serves as a routine update and filing of exhibits.

Why It Matters

This 8-K filing indicates Lipocine Inc. is providing updates and submitting necessary financial documents to the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — This filing appears to be a routine administrative filing with no immediately apparent material adverse information.

Key Players & Entities

  • Lipocine Inc. (company) — Registrant
  • September 30, 2024 (date) — Date of Earliest Event Reported
  • Delaware (jurisdiction) — State of incorporation
  • 675 Arapeen Drive, Suite 202 (address) — Principal executive offices
  • Salt Lake City, Utah 84108 (address) — Principal executive offices
  • (801) 994-7383 (phone_number) — Registrant's telephone number

FAQ

What specific 'Other Events' are being reported by Lipocine Inc. in this 8-K filing?

The provided text does not specify the details of the 'Other Events' beyond listing it as an item information category.

When was the earliest event reported in this Form 8-K?

The earliest event reported was on September 30, 2024.

What is Lipocine Inc.'s state of incorporation?

Lipocine Inc. is incorporated in Delaware.

What is the principal executive office address for Lipocine Inc.?

The principal executive office is located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

What is the SEC file number for Lipocine Inc.?

The SEC file number for Lipocine Inc. is 001-36357.

Filing Stats: 442 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2024-09-30 09:35:22

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: September 30, 2024 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.